Pre-made Afelimomab benchmark antibody (Fab Fusion, anti-TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Afelimomab benchmark antibody (Fab Fusion, anti-TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Afelimomab (MAK 195F) is an anti-TNF¦Á monoclonal antibody. Administration of afelimomab reduces the concentration of interleukin-6 in patients with sepsis, but reduces mortality only marginally.[1][2]
| Products Name (INN Index) | Pre-Made Afelimomab Biosimilar, Fab Fusion, Anti-Tnf Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody |
|---|---|
| INN Name | afelimomab |
| Target | TNF |
| Format | Fab Fusion |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | F(ab')2 – G3 – kappa |
| VD LC | F(ab')2 – G3 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Abbott?Laboratories (Abbott Park IL USA) / Knoll Pharmaceutical (Mount Olive NJ USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNF |
| Package |
